<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>hepatocellular carcinoma combination therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/hepatocellular-carcinoma-combination-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 17 Oct 2025 13:22:20 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>hepatocellular carcinoma combination therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Boosting Liver Cancer Treatment: Radiation Plus Immunotherapy</title>
		<link>https://bioengineer.org/boosting-liver-cancer-treatment-radiation-plus-immunotherapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Oct 2025 13:22:04 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[HCC survival outcomes]]></category>
		<category><![CDATA[hepatocellular carcinoma combination therapy]]></category>
		<category><![CDATA[liver cancer treatment meta-analysis]]></category>
		<category><![CDATA[radiation plus targeted agents]]></category>
		<category><![CDATA[SBRT and immunotherapy synergy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/boosting-liver-cancer-treatment-radiation-plus-immunotherapy/</guid>

					<description><![CDATA[In the relentless pursuit of more effective treatments for advanced hepatocellular carcinoma (HCC), a groundbreaking meta-analysis recently published has cast new light on an emerging multimodal approach. Researchers have rigorously evaluated the combination of stereotactic body radiation therapy (SBRT) with targeted agents and immunotherapies, revealing significant survival benefits without exacerbating treatment-related toxicities. This comprehensive investigation, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">282777</post-id>	</item>
	</channel>
</rss>
